41019-45-8

Usage

Uses

Used in Pharmaceutical Industry:
5-(4-Chlorophenyl)-2-furoic acid is used as a key intermediate in the synthesis of 5-(5-aryl-2-furyl)-tetrazol-1-ylacetic acids. These acids are further utilized in the production of semisynthetic cephalosporins, which are a class of antibiotics known for their broad-spectrum antimicrobial properties. The application of 5-(4-CHLOROPHENYL)-2-FUROIC ACID in the pharmaceutical industry is primarily due to its role in the development of new and effective antibiotics to combat bacterial infections.
Used in Chemical Research:
As a 5-aryl-2-furancarboxylic acid derivative, 5-(4-chlorophenyl)-2-furoic acid is also employed in various chemical research applications. It can be used to study the structure-activity relationships of different furan-based compounds and to explore their potential applications in various fields, such as materials science, agrochemistry, and medicinal chemistry. 5-(4-CHLOROPHENYL)-2-FUROIC ACID's unique structure and reactivity make it a valuable tool for researchers in the field of organic chemistry.

InChI:InChI=1/C11H7ClO3/c12-8-3-1-7(2-4-8)9-5-6-10(15-9)11(13)14/h1-6H,(H,13,14)

Upstream product

• 34035-03-5 5-(4-chlorophenyl)-2-furaldehyde 
• 88-14-2 2-furanoic acid 
• 106-47-8 4-chloro-aniline 
• 585-70-6 5-bromo-furan-2-carboxylic acid 
• 1679-18-1 4-Chlorophenylboronic acid 
• 41019-40-3 methyl 5-(4-chlorophenyl)furan-2-carboxylate 
• 106-39-8 bromochlorobenzene 
• 27329-70-0 5-formylfurane-2-boronic acid 
• 2527-99-3 methyl 5-bromo-2-furoate 
• 98-01-1 furfural 

Downstream Products

• 139268-17-0 6-<5-(4-Chlorophenyl)-2-furyl>-3-o-hydroxyphenyl-1,2,4-triazolo<3,4-b>-1,3,4-thiadiazole 
• 139268-18-1 6-<5-(4-Chlorophenyl)-2-furyl>-3-p-chlorophenyl-1,2,4-triazolo<3,4-b>-1,3,4-thiadiazole 
• 139268-13-6 6-<5-(4-Chlorophenyl)-2-furyl>-3-methyl-1,2,4-triazolo<3,4-b>-1,3,4-thiadiazole 
• 139268-14-7 6-<5-(4-Chlorophenyl)-2-furyl>-3-ethyl-1,2,4-triazolo<3,4-b>-1,3,4-thiadiazole 
• 139268-15-8 6-<5-(4-Chlorophenyl)-2-furyl>-3-propyl-1,2,4-triazolo<3,4-b>-1,3,4-thiadiazole 
• 139268-16-9 6-<5-(4-Chlorophenyl)-2-furyl>-3-phenyl-1,2,4-triazolo<3,4-b>-1,3,4-thiadiazole 
• 57753-80-7 5-(4-chloro-phenyl)-furan-2-carbonyl chloride 
• 80174-08-9 5-(4-Chloro-phenyl)-furan-2-carbonyl azide 
• 41019-40-3 methyl 5-(4-chlorophenyl)furan-2-carboxylate 
• 355385-47-6 (R)-N-(1-Azabicyclo[2.2.2]oct-3-yl)(5-(4-chlorophenyl)furan-2-carboxamide) 
• 65385-49-1 1-(3-bromo-phenyl)-4-[5-(4-chloro-phenyl)-furan-2-carbonyl]-piperazine 
• 1026766-37-9 5-(4-chlorophenyl)-N-(5-(cyclopropylcarbamoyl)-2-methylphenyl)furan-2-carboxamide 
• 868145-94-2 6-[5-(4-chlorophenyl)furan-2-yl]-3-(2-methylfuran-3-yl)[1,2,4]triazolo[3,4-b][1,3,4]thiadiazole 

Relevant academic research and scientific papers

Furan-2-carboxamide derivative, a novel microtubule stabilizing agent induces mitotic arrest and potentiates apoptosis in cancer cells

The vital role played by microtubules in the cell division process, marks them as a potential druggable target to decimate cancer. A novel furan-2-carboxamide based small molecule, is a selective microtubule stabilizing agent (MSA) with IC50 ranging from 4 μM to 8 μM in different cancer cell lines. Inhibition of tubulin polymerization or stabilization of tubulin polymers abrogates chromosomal segregation during cell division, results in cell cycle arrest and leads to cell death due to the delayed repair mechanism. A novel furan-2-carboxamide based small molecule exhibited potent anti-proliferative and anti-metastatic property In-Vitro against the panel of cancer cells. Annexin V-FITC/PI, double staining reveals potent cytotoxic effect of SH09 against HeLa cells. FACS analysis displays induction of G2/M arrest and accumulation of subG1 population of cells upon treatment with SH09. Molecular docking study unveils SH09 binding affinity to the Taxol binding pocket of tubulin proteins and MM-GBSA also confirms strong binding energies of SH09 with tubulin proteins.

Discovery of a series of 5-phenyl-2-furan derivatives containing 1,3-thiazole moiety as potent Escherichia coli β-glucuronidase inhibitors

Gut microbial β-glucuronidases have drawn much attention due to their role as a potential therapeutic target to alleviate some drugs or their metabolites-induced gastrointestinal toxicity. In this study, fifteen 5-phenyl-2-furan derivatives containing 1,3

Synthesis of arylfuran derivatives as potential antibacterial agents

Bacterial infections represent a serious health care problem mainly due to the misuse and overuse of antibiotics, with consequent emergence of multidrug resistant bacterial strains. Then, because the urgent need to find novel and alternative antibacterial agents, the present work focuses on the synthesis of arylfuran derivatives with potential antimicrobial activity. Eighteen arylfuran derivatives were synthesized and evaluated for their antibacterial activity against Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. Among them, seven compounds containing an amino group in their structure showed activity, with compound 24 being the most effective against both Gram-negative (E. coli, MIC = 49 μM) and Gram-positive (S. aureus, MIC = 98 μM) bacteria, besides having exhibited a modest activity against P. aeruginosa (MIC = 770 μM). In addition, based on in silico studies, this is a druglike compound since it does not violate any rules for predicting oral bioavailability. In this context, the significant antibacterial potential and the low similarity with known antibiotics indicate the innovative aspect of compound 24.

Carbon–Carbon Bond Formation for the Synthesis of 5-Aryl-2-Substituted Furans Catalyzed by K3[Fe(CN)6]

An efficient method for the carbon–carbon bond formation at C-5 position of 2-substituted furans to provide a range of π-diverse 5-aryl-2-substituted furan derivatives in 58–80% yield has been reported. The method employs several advantages such as use of catalytic amount of K3[Fe(CN)6] under mild conditions and short reaction time with high yields. Also, a variety of anilines with a variety of functional groups can be employed for the synthesis of 5-aryl-2-substituted furans. Graphic Abstract: [Figure not available: see fulltext.]

2-furoylamide compound and preparation and application thereof

The invention discloses a 2-furancarboxamide compound and a preparation method and application thereof. The 2-furancarboxamide compound is obtained by reacting a compound as shown in a formula II with9H-pyridino[3,4-b]indole in the presence of an acid-bin

Thiazolidin-2-cyanamides derivatives as novel potent Escherichia coli β-glucuronidase inhibitors and their structure–inhibitory activity relationships

Gut microbial β-glucuronidases have the ability to deconjugate glucuronides of some drugs, thus have been considered as an important drug target to alleviate the drug metabolites-induced gastrointestinal toxicity. In this study, thiazolidin-2-cyanamide de

Synthesis and bioactivity of phenyl substituted furan and oxazole carboxylic acid derivatives as potential PDE4 inhibitors

In this present study, a series of 5-phenyl-2-furan and 4-phenyl-2-oxazole derivatives were designed and synthesized as phosphodiesterase type 4 (PDE4) inhibitors. In vitro results showed that the synthesized compounds exhibited considerable inhibitory ac

Synthesis and SAR of 5-aryl-furan-2-carboxamide derivatives as potent urotensin-II receptor antagonists

The synthesis and biological evaluation as potential urotensin-II receptor antagonists of a series of 5-arylfuran-2-carboxamide derivatives 1, bearing a 4-(3-chloro-4-(piperidin-4-yloxy)benzyl)piperazin-1-yl group, are described. The results of a systemat

Novel S-Thiazol-2-yl-furan-2-carbothioate Derivatives as Potential T3SS Inhibitors against Xanthomonas oryzae on Rice

Bacterial leaf blight (BLB) caused by Xanthomonas oryzae pv oryzae (Xoo) is considered as the most destructive disease of rice. The use of bactericides is among the most widely used traditional methods to control this destructive disease. The excessive an

Synthesis and biological evaluation of 2,5-disubstituted furan derivatives as P-glycoprotein inhibitors for Doxorubicin resistance in MCF-7/ADR cell

Multidrug resistance (MDR) is a tendency in which cells become resistant to structurally and mechanistically unrelated drugs, which is mediated by P-glycoprotein (P-gp). It is one of the noteworthy problems in cancer therapy. As one of the most important